Our new suite of Antygen™ SARS-CoV-2 antibody detection platforms will enable researchers, pharmaceutical companies, and vaccine developers to closely monitor the immune effects induced by COVID-19 disease, vaccines, and therapies. We built them because all of our futures now depend on the body’s ability to make antibodies to SARS-CoV-2, the virus that causes pandemic COVID-19 disease.
Four new SARS-CoV-2 antibody detection platforms.
SARS-CoV-2 HuProt™: The world’s largest human protein library; now with SARS-CoV-2. Profile autoantibodies versus >21,000 full-length human proteins alongside SARS-CoV-2 S1 receptor-binding spike and nucleocapsid proteins.
VirScan™ + SARS-CoV-2: Epitope-level antiviral antibody profiling of the human virome via T7 phage display and immunonprecipitation sequencing (PhIP-Seq) paired with our SMI or 2-in-1 SARS-CoV-2 microarrays.